Veracyte to Acquire C2i Genomics to Add Whole-Genome MRD Capabilities

Veracyte Acquires Decipher Biosciences

February 3, 2021

Biotechnology

Veracyte, Inc. has entered into a definitive agreement to acquire Decipher Biosciences, a commercial-stage precision oncology company focused on urologic cancers, for $600 million in total consideration ($250 million cash and up to $350 million in stock). The acquisition expands Veracyte’s genomic cancer diagnostics menu, adds Decipher’s commercial tests and data assets, and is expected to accelerate revenue growth and global market reach.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.

CD&R, Merck GHI and McKesson Ventures Recapitalize M2GEN

March 17, 2021

Healthcare Services

Clayton, Dubilier & Rice (CD&R) led a recapitalization of oncology data and informatics company M2GEN, with strategic investments from Merck Global Health Innovation Fund and McKesson Ventures. The transaction — which closed with terms undisclosed — positions CD&R as the largest shareholder and will fund growth of M2GEN's linked clinical and genomic data assets and expanded technology and informatics capabilities.

Charles River Laboratories Acquires Cognate BioServices

February 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Cognate BioServices for approximately $875 million in cash, expanding Charles River's capabilities into the high-growth cell and gene therapy CDMO sector. Cognate, headquartered in Memphis, Tennessee with over 500 employees, will provide Charles River integrated cell and gene therapy development, testing, and CGMP manufacturing capabilities; the deal was expected to close by end of Q1 2021.

Vertex Pharmaceuticals Acquires ViaCyte for $320M

July 11, 2022

Biotechnology

Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.